CPHI
China Pharma Holdings, Inc.
There isn't enough reported data to score CPHI yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CPHI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Stable | |
| Weak |
CPHI's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CPHI PE Valuation
CPHI has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CPHI Forward outlook
There aren't enough analyst estimates for CPHI to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CPHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.42 | +$1.08 |
| Q1 2026 | -$0.54 | +$1.70 |
| Q4 2025 | -$0.74 | +$1.96 |
| Q3 2022 | -$35.00 | +$10.00 |
| Q2 2022 | -$35.00 | +$10.00 |
| Q1 2022 | -$35.00 | $0.00 |
| Q4 2021 | -$35.00 | $0.00 |
| Q3 2021 | -$45.00 | +$190.00 |
CPHI lost $0.42 per share over the past year, a smaller loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CPHI on earnings quality, reporting a profit while its opponent remains loss making.
CPHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $948.3K | -7.5% |
| Q1 2026 | $983.5K | -13% |
| Q4 2025 | $1.2M | +8.1% |
| Q3 2025 | $756.2K | -31% |
| Q2 2025 | $1M | +11% |
| Q1 2025 | $1.1M | -17% |
| Q4 2024 | $1.1M | -47% |
| Q3 2024 | $1.1M | -39% |
CPHI's revenue has slid since its 2020 peak: $948,340 last quarter, down 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -151% | -87 points |
| Q1 2026 | -114% | -47 points |
| Q4 2025 | -98% | +7.6 points |
| Q3 2025 | -83% | +16 points |
| Q2 2025 | -64% | +87 points |
| Q1 2025 | -67% | +0.1 points |
| Q4 2024 | -105% | -50 points |
| Q3 2024 | -99% | -59 points |
CPHI's operating margin was −151% last quarter, down 87 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CPHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CPHI on profitability, with a higher operating margin.
CPHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2025 | -$237.6K | -$190.6K |
| Q2 2025 | $291.1K | +$363.9K |
| Q1 2025 | -$116.1K | +$469K |
| Q3 2024 | -$47K | -105% |
| Q2 2024 | -$72.7K | +$143.7K |
| Q1 2024 | -$585.2K | +$883.1K |
| Q4 2023 | -$22.3K | -104% |
| Q3 2023 | $1M | +$1M |
CPHI has the stronger cash trend. Its trailing FCF is up 110% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
CPHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +58% | +14.9M shares |
| 1 year | +1142% | +37.3M shares |
| 3 years | +40409% | +40.4M shares |
| 5 years | +46392% | +40.4M shares |
| Available history | +46392% | +40.4M shares |
CPHI has 41M diluted shares, up 1142% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CPHI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CPHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 1,068.6x | High |
| Q1 2022 | 217.7x | High |
| Q4 2021 | 20.8x | High |
| Q1 2021 | 92.7x | High |
| Q4 2020 | 42.3x | High |
CPHI's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CPHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 5.4 | Oversold |
CPHI's weekly RSI is 41 (neutral) and its Stochastic is 5 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CPHI PE vs Healthcare Sector
CPHI has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CPHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 18% below |
| 20 week MA | $0.84 | 33% below |
| 50 week MA | $0.86 | 35% below |
| 100 week MA | $1.37 | 59% below |
| 200 week MA | $5.78 | 90% below |
CPHI is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CPHI on trend strength, trading above more of its moving averages.
CPHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $121.5 | $223.8 | +84% |
| 2021 | $223.8 | $215.1 | -3.9% |
| 2022 | $215.1 | $58.3 | -73% |
| 2023 | $58.3 | $6.05 | -90% |
| 2024 | $6.05 | $2.10 | -65% |
| 2025 | $2.10 | $1.29 | -39% |
| 2026 YTD | $1.29 | $0.56 | -57% |
CPHI has finished five years in a row lower, and it's down 57% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CPHI on returns for 2026, with the stronger performance.